Drug intelligence / Profile preview

TG4010 + cisplatin + gemcitabine

Development stage: Unknown
Lead developer: Transgene
Modality: Small Molecules, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intravenous

Overview

TG4010 + cisplatin + gemcitabine is a combination therapy consisting of a therapeutic cancer vaccine (TG4010) and standard chemotherapy (cisplatin + gemcitabine). TG4010 is a modified vaccinia Ankara (MVA) viral vector expressing the tumor-associated antigen MUC1 and interleukin-2 (IL-2). This combination is designed to stimulate the immune system against MUC1-expressing tumor cells while simultaneously attacking cancer cells with chemotherapy.

Targets

MUC1 (Mucin-1 Antigen)DNA

Beyond the preview

Go deeper on TG4010 + cisplatin + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TG4010 + cisplatin + gemcitabine.

Explore the full profile